ABSTRACT TEMPLATE for Company Presentations

Questions for categories: Biotech/Pharma or **Medical Devices** or **Health IT/Digital**

Investment Rational

Genetika+ is developing a personalized-medicine test for Depression finding the best treatment for each patient. 300 million people suffer globally representing a $10Bn TAM. We're running retrospective clinical trials through the NIH and have initiated partnerships with Sheba and Jefferson Hospitals. The management has scientific expertise from Oxford, Harvard, and Columbia and leadership experience from White-House Backed Pairnomix and Teva.

Business Strategy

The Genetika+ blood-test, RxMine, will be marketed as a Lab Developed Test (LDT), sold directly to physicians/psychiatrist at a $2000 price point, in keeping with competitors pricing. Reimbursement codes are currently available from Medicaid/Medicare/Private insurers allowing for partial reimbursement. Long term revenue streams include pharmaceutical screening services for patient stratification in clinical trials and new drug development, and data/sample sales.

Core Technology

RxMine combines genetics, patient-history and neurobiology (by screening neurons derived from patient blood via stem-cells) predicting the best drug for each patient, avoiding the trial-and-error process. Compared with our genetics-only competitors (success rate 15%) this technology is a first in enabling testing neuronal functional output individually for each patient, mimicking the brain responses, powerfully improving personalized medicine in CNS-related diseases.

Product Profile/Pipeline

RxMine, sold out of Genetika+ labs, is aimed at patients failing first-line medication ($10Bn TAM). We completed our first retrospective clinical studies and publication and have additional trials underway with Sheba and Jefferson. We are also initiating our second product line, pharmaceutical partnerships, for new indications for existing drugs.

What's Next?

Having established novel biomarkers, built our functional MVP and raised our Series A from Boston based VCs, we are initated HEOR trials and prospective studies. Next steps are reduced TAT/COGs and initiation of the Regulatory/Reimbursement Roadmap toward US market entry.